KANKAKEE COUNTY, IL – CSL Behring has made a significant breakthrough in the treatment of hemophilia B with the FDA approval of their revolutionary gene therapy, HEMGENIX®.
The one time dose life-changing therapy, priced at $3.5 million, offers hope and relief to individuals suffering from this severe blood disorder. By addressing the genetic cause of hemophilia B, HEMGENIX® has the potential to transform the lives of patients, significantly reducing bleeds and the need for frequent infusions.
The first patient in the United States has already received this groundbreaking treatment this month, marking a momentous milestone in medical history. With a single infusion of HEMGENIX®, patients have experienced a remarkable reduction or elimination of the need for prophylactic treatment.
The therapy not only offers long-term health benefits but also has the potential to generate substantial cost savings for the healthcare system.
While the price tag of $3.5 million may seem significant, it is an investment that can provide a lifetime of freedom and relief from the burden of hemophilia B.
